SCHEMBL6404524

SCHEMBL6404524

COC(=O)[C@H](O)c1ccccc1OC

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.47
HTT P42858 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
KMT2A Q03164 2/20 0.46
LPAR1 Q92633 1/20 0.45
KDM4E B2RXH2 1/20 0.45
LMNA P02545 1/20 0.45
CYP1A2 P05177 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
CA1 P00915 2/20 0.45
CA2 P00918 2/20 0.45
ACHE P22303 1/20 0.45
CTSD P07339 1/20 0.44
CA12 O43570 1/20 0.44
CA4 P22748 1/20 0.44
CA7 P43166 1/20 0.44
CA9 Q16790 1/20 0.44
CA14 Q9ULX7 1/20 0.44
KCNK3 O14649 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7443221 1.00 POLB (0.47) POLBHTTNPSR1L3MBTL1KMT2A
SCHEMBL1900944 0.86 L3MBTL1 (0.49) L3MBTL1KMT2AKDM4EKCNK3KCNK9
SCHEMBL22283800 0.84 MEN1 (0.49) POLBHTTNPSR1L3MBTL1KMT2A
SCHEMBL22144400 0.84 MEN1 (0.49) POLBHTTNPSR1L3MBTL1KMT2A
SCHEMBL10575353 0.84 POLB (0.44) POLBHTTNPSR1L3MBTL1KMT2A
SCHEMBL1822261 0.83 CA1 (0.39) POLBHTTNPSR1L3MBTL1KMT2A
SCHEMBL2065727 0.83 PPARG (0.43) POLBHTTNPSR1L3MBTL1KMT2A
SCHEMBL6400516 0.82 KMT2A (0.55) POLBHTTNPSR1L3MBTL1KMT2A
SCHEMBL13170107 0.82 POLB (0.49) POLBHTTNPSR1L3MBTL1KMT2A
SCHEMBL503436 0.82 KMT2A (0.55) POLBHTTNPSR1L3MBTL1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6846835-B2 Treating chronic obstructive pulmonary disease, chronic bronchitis, asthma, chronic respiratory tract obstruction, fibroid lung, pulmonary emphysema or rhinitis BANYU PHARMACEUTICAL CO., LTD. (JP) 2005-01-25 US disclosed
US-20030191316-A1 Ester derivatives MSD K.K. (JP) 2003-10-09 US disclosed
US-4595685-A Pharmaceuticals HOECHST AKTIENGESELLSCHAFT (DE) 1986-06-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030191316-A1 Ester derivatives CHRM3, CHRM2, CHRM1 POLB 2575/4885HTT 4110/4885NPSR1 287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.